European Society of Cardiology Congress 2021: Primary Care Preview
The ESC Congress 2021, Aug 27-30, 2021, is here. For primary care, we highlight the "Hot Lines" clinical trial presentations where new data from novel trials will premier.
Finerenone Approved as First-in-Class Treatment for Chronic Kidney Disease Associated with Type 2 Diabetes
The first nonsteroidal mineralocorticoid receptor antagonist to be approved for adults with T2D-associated CKD fills a significant treatment void for millions of patients.
SGLT2 Inhibitors: 4 Questions Go Back to Basics
The SGLT-2 inhibitor class, originally approved as antihyperglycemic agents for T2D, has proven "pluripotent," adding indications for related conditions. Test your knowledge of a few basic facts.
GLP-1 RA, Insulin More Effective Second-line vs Sulfonylurea, DPP-4 Inhibitor for T2D
Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.
Efpeglenatide Reduces CV Risk, Progression of Renal Disease in High-risk T2D Population
ADA 2021: The investigational exendin-4-based GLP-1 RA was associated with a 27% decrease in risk for a CV event and a 32% reduction in risk for CKD progression.
ADA 2021: Renal, CV Protection in FIDELIO-CKD Unaffected by Baseline GLP-1 RA Use
ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not GLP-1 receptor agonists were on board at study baseline.
ADA 2021: Renoprotection with Finerenone Consistent Regardless of SGLT2 Inhibitor Use
ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not SGLT2 inhibitors were on board at study baseline.
Clinical Trial Updates at the ADA Scientific Sessions 2021: A few primary care musts
The American Diabetes Association 2021 Scientific Sessions run from June 25 to 29. This short slide show highlights 6 clinical trial updates that are a "must see" for primary care clinicians.
Prediabetes Subphenotyping: A Novel Approach to Type 2 Diabetes Prevention
New research proposes pathophysiology-based subphenotyping of individuals at increased risk for T2D; 6 are suggested to help refine screening, prevention, and treatment.
A Test of CKD IQ: 10 Questions for Primary Care Clinicians
CKD IQ Test Preview: When should you suspect kidney disease? What measure is used to define chronic kidney disease? What UACR test result indicates albuminuria? Good luck.
How to Slow CKD Progression: Treatment Essentials for Primary Care
Most patients with chronic kidney disease are treated in primary care where the primary goal is twofold: slow progression and prevent complications. Find essentials of both, here.
ACC.21: Finerenone Shows Potential to Delay Afib Onset in Patients with CKD, T2D
ACC.2021: A new analysis of FIDELIO-DKD found patients with chronic kidney disease and type 2 diabetes were about 30% less likely to develop atrial fibrillation vs those treated with placebo.
Chronic Kidney Disease: Diagnosis in Primary Care
Early detection of chronic kidney disease in primary care provides a significant opportunity to avoid complications and slow the loss of renal function. Topline guidance, here.
Defining Chronic Kidney Disease in Primary Care: Management, Complications, Risk, Referral
Primary care clinicians have an essential role in the diagnosis and treatment of chronic kidney disease. Click through a review of the basics.
Diabetes Management in CKD: 10 Top Takeaways from KDIGO 2020
The 2020 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline integrates new treatments and practices with existing management strategies for CKD patients with diabetes.
FDA Approves Dapagliflozin to Treat Chronic Kidney Disease in Adults at Risk of Progression, Regardless of Diabetes Status
Dapagliflozin is the first SGLT-2 inhibitor to receive FDA approval for the treatment of CKD, regardless of diabetes status.
ACP: Clyde Yancy, MD, MSc Reviews Advances in Heart Failure Research and Treatment
ACP: Clyde W Yancy, MD, gave a comprehensive update on a year's worth of pivotal science in treatment of heart failure. Here are the highlights.
George Bakris, MD: Heart Failure, Renal Disease, CV Risk Research is on Fire
Video: George Bakris, MD says over the next 3 years there is going to be an "explosion" in the number of studies we see in heart failure, diabetic kidney disease, and CV risk in general.
Top Content 2020: Preventive Cardiology
The most popular features in preventive cardiology this year were interviews with thought leaders on management of diabetes, hypertension, and hypercholesterolemia.
SGLT2 Inhibitors Enter Vast Treatment Void for High-risk CKD Patients
Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains.
DAPA-CKD Investigator: "PCPs Should be First-line Prescribers of SGLT2 Inhibitors"
Primary care clinicians should be the first to prescribe SGLT2 inhibitors for many reasons, as explained by Prof Jonathan McMurray in this Patient Care interview.
Professor John McMurray Highlights DAPA-CKD Trial Outcomes
DAPA-CKD investigator Professor John McMurray details the trial and renal and cardiovascular outcomes for Patient Care Online.
DAPA-CKD Trial Findings Could Transform CKD Therapy
AHA: DAPD-CKD investigator Prof John McMurray talks to Patient Care about the “revolutionary” findings he will highlight at the AHA sessions on opening day.
George Bakris, MD, Lauds FIDELIO-CKD Findings, Discusses Finerenone
Finerenone, a non-steroidal, selective MRA, has distinct advantages over current treatments for diabetic kidney disease. Dr Bakris details these and the FIDELIO results.
4 Questions for PCPs on Prevention and Management of Cardiometabolic Diseases
Waist circumference measures, complementary antihypertensives, appropriate exercise levels for T2D patients--test what you know about cardiometabolic risk and management.
Kidney Week: Dapagliflozin Renoprotective, Cardioprotective in CKD Patients
Dapagliflozin is renoprotective and cardioprotective in chronic kidney disease patients, suggests a secondary analysis of the DAPA-CKD trial presented at Kidney Week 2020.
Finerenone Slows Renal Decline, Improves CV Outcomes in FIDELIO-DKD
The investigational mineralocorticoid receptor antagonist slowed progression to renal failure by 18% and reduced the composite cardiovascular outcome by 14%, authors report.
Empagliflozin Receives FDA Fast Track Designation for Treatment of Kidney Disease
FDA Fast Track designation is to investigate whether the diabetes medication can also reduce kidney disease progression.
Heart Failure, Other CVD Increase Risk for ESRD
Cardiovascular diseases, particularly heart failure, were found significantly and independently associated with end-stage renal disease in a new analysis.
Hypertension in Dialysis Patients: Primary Care Primer
When CKD 4-5 progresses to ESRD, how should hypertension management be changed? Or, should it?
